Momenta Phama (MNTA) Tops Q1 EPS by 14c, Revenues Beat

Momenta Phama (NASDAQ: MNTA) reported Q1 EPS of ($0.34), $0.14 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $8.89 million versus the consensus estimate of $4.33 million.

“Despite the turbulence imposed by the COVID-19 pandemic, Momenta has remained focused on advancing our development pipeline for rare, immune-mediated diseases,” said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. “We are targeting key readouts from our lead programs by the end of the third quarter. These readouts will include interim proof-of-concept data from nipocalimab in MG and data from Part B of our Phase 1/2 study of M254 in ITP. We expect data from both programs will further demonstrate the potential of these programs, each with franchise opportunities across a range of large market auto- and alloimmune diseases. Finally, we remain in a strong corporate position, with cash to fund operations through at least the third quarter 2021, as we continue to leverage our platform for growth.”

For earnings history and earnings-related data on Momenta Phama (MNTA) click here.

You May Also Be Interested In

• Citi agrees to acquire rewards platform Kard Financial
• Innovaro (INV) Misses Q2 EPS by 9c
• KULR Technology Group (KULR) Misses Q2 EPS by 39c